WEDNESDAY, June 10, 2026 (NewsDay News) — Continued use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in early pregnancy does not appear to be associated with an increased risk of stillbirth, abnormal fetal growth, or major birth defects. Annals of internal diseases.
Jeremy Brown, Ph.D., from the Harvard Chan School of Public Health in Boston, and colleagues estimated the risk of stillbirth, abnormal fetal growth, and MCM with GLP-1 RA injection in early pregnancy in an observational cohort of pregnant women aged 16 to 55 years in the last days of the GLP-901 treatment period. (LMP); 3,572 pregnancies were included in the study. A randomized controlled trial with two treatment strategies: continuation of spraying in the first trimester or no continuation.
The researchers found that the risk of live birth weight was 29.7 and 27.1 percent with continuation and no continuation, respectively (adjusted hazard ratio, 1.09; 95 percent confidence interval, 0.98 to 1.23). Overall, 1,443 (57.1 percent) of 2,529 live-birth pregnancies received at least one GLP-1 RA dispensation after LMP, and 1,499 (829 with continuous dispensation) were associated with a newborn. For continuation and noncontinuation, weighted prevalence ratios were 1.29 (95 percent confidence interval, 0.82 to 2.06), 1.08 (95 percent confidence interval, 0.84 to 1.40), and 1.21 (95 percent confidence interval, for older age, for younger age, 0.82). age and MCM, respectively.
The authors write, “accumulating evidence is reassuring regarding the risk of failure after accidental exposure in women who become pregnant while using GLP-1 RA.”
Abstract / Full Text (subscription or payment may be required)
